QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
IPO Year:
Exchange: NYSE
Website: qiagen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | $49.00 | Buy → Hold | HSBC Securities |
| 6/27/2024 | $50.00 | Peer Perform → Outperform | Wolfe Research |
| 12/19/2023 | $44.00 | Equal Weight | Wells Fargo |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 12/7/2023 | $50.00 | Neutral → Buy | Goldman |
| 9/12/2023 | $50.00 | Outperform | Robert W. Baird |
| 5/23/2023 | Equal-Weight → Overweight | Morgan Stanley | |
| 10/18/2022 | Equal-Weight | Morgan Stanley | |
| 1/18/2022 | Hold → Buy | DZ Bank | |
| 12/14/2021 | $58.00 → $60.00 | Equal-Weight | Wells Fargo |
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0448UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID:
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supporting targeted investments. Adjusted diluted earnings per share (EPS) were $0.55, and results at CER of $0.55 were above the outlook for at least $0.52 CER. QIAGEN has updated its FY
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID: 8081
Venlo, the Netherlands, April 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the first quarter of 2024. Net sales declined 5% to $459 million, while results at constant exchanges rates (CER) of $462 million were above the outlook for at least $455 million CER. The adjusted operating income margin rose to 25.7% from 25.6% in the year-ago period on realized efficiency gains while supporting investments into the portfolio. Adjusted diluted earnings per share (EPS) were $0.46, and results at CER were $0.47 and above the outlook for at least $0.44 CER. For 2024, QIAGEN has reaffirmed its outlook for net sales of at least
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID: 2903795To avoid
Venlo, the Netherlands, Feb. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the fourth quarter and full-year 2023. Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non-COVID-19 portfolio. Total sales for Q4 2023 rose 2% (+1% CER) to $509 million from Q4 2022, a period marked by significant COVID-19 sales. Adjusted diluted earnings per share (EPS) were $0.55 CER and above the outlook for at least $0.53 CER. Full-year 2023 sales declined 8% to $1.97 billion, achieving the outlook for $1.97 billion CER sales and were
Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193UK: +44 (0)330 165 3655GER: +49 (
Venlo, the Netherlands, Oct. 30, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced results for the third quarter and first nine months of 2023. Net sales results of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the non-COVID-19 portfolio. Overall sales results for Q3 2023 declined 5% (-6% CER) to $476 million from Q3 2022, a period marked by significant COVID-19 sales contributions. Adjusted diluted earnings per share (EPS) were $0.50, and results of $0.50 CER were above the outlook for at least $0.48 CER. QIAGEN has reaffirmed its full-year 2023 outlook
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 London time / 09:00 New York time. (For Europe: Due to the U.S. time switch, our conference call will be held one hour earlier than usual.) Three options for joining the conference call
Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper respiratory infections in outpatient settings and covers five common viral causes of illness: influenza A, influenza B, human rhinovirus, respiratory syncytial virus (RSV) and SARS-CoV-2. The panel leverages QIAstat-Dx's ability
Venlo, the Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced key updates to its sample technologies solutions for non-invasive liquid biopsy applications for use in research and clinical applications such as oncology, prenatal care and organ transplantation. "The introduction of these new kits and the updates to our EZ2 Connect platform underline QIAGEN's commitment to advancing liquid biopsy technologies," said Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN. "These enhancements not only expand our portfolio to meet the diverse needs of our customers but also reinforce our leadershi
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0448UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID:
Venlo, the Netherlands, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Thousands of healthcare professionals, advocates, and public policymakers from over 170 countries are set to participate from October 8-11 in the annual Global TB Summit, sponsored by QIAGEN, as the world confronts the resurgence of tuberculosis as one of the deadliest infectious diseases. After a decline of about 2% per year between 2020 and 2022, the tuberculosis incident rate rose by 3.9% in 2022. An estimated 10.6 million people worldwide fell ill with tuberculosis in 2022, leading to 1.3 million deaths. This made tuberculosis the second leading infectious disease killer after COVID-19.1 According to the World Health Organ
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
Venlo, the Netherlands, Sept. 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics. The instrument and accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe. QIAcuityDx streamlines clinical testing by providing highly precise, absolute quantitation of target DNA and RNA, supporting applications with less invasive liquid biopsies. These capabilities make it an ideal tool for monitoring cancer progression, complementing routine cancer diagnoses, which are typically perfo
Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation (IVDR). This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement underscores QIAGEN's commitment to meeting the highest standards of safety, quality, and performance, as it has already transitioned 80 percent of over 180 products to the new regulatory framework. The new IVD regulati
Venlo, The Netherlands, and Hombrechtikon, Switzerland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PreAnalytiX GmbH, a joint venture between QIAGEN N.V. (NYSE:QGEN, Frankfurt, Prime Standard: QIA))) and BD ((Becton, Dickinson and Company, NYSE:BDX), today announced the launch of the PAXgene® Urine Liquid Biopsy Set, which enables the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). The new set will be commercialized by QIAGEN. The PAXgene Urine Liquid Biopsy Set addresses the challenge of gaining access to cfDNA from urine through an integrated preservation solution. This easy-to-use
Venlo, the Netherlands, and Germantown, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data. The multi-year agreement between QIAGEN's subsidiary Verogen and Bode extends the long-standing partnership of two leading companies in forensic investigative genetic genealogy (FIGG) to further accelerate the use of GEDmatch
Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced an important milestone with the launch of 100 new assays for its digital PCR (dPCR) platform QIAcuity for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring. These new assays are available through QIAGEN's comprehensive GeneGlobe platform which integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. QIAGEN has so far launched more than 130 new assays this year, exceeding the 2024 goal and adding to the existing to
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics.The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) using DNA technologies such as next-generation sequencing (NGS) and forensic investigative genetic genealogy (FIGG).Within this long-term partnership, QIAGEN supports the Snow Molecular Anthropology Lab with a MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System.
Wolfe Research analyst Doug Schenkel upgrades Qiagen (NYSE:QGEN) from Peer Perform to Outperform and announces $50 price target.
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) results. Bristol Myers Squibb added adagrasib via its $5 billion Mirati Therapeutics Inc. deal. The approval is based on results from cohorts of the Phase 1/2 KRYSTAL-1 open-label study, which e
CORRECTION : JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54 -Analyst Name Updated (Article Originally Published on 18th June) .
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday. Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell sharply in today's pre-market trading after the company rejected unsolicited takeover bids, citing undervaluation. Vanda Pharmaceuticals shares dipped 6% to $5.96 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Trump Media & Technology Group Corp. (NASDAQ:DJT) shares dipped 7.7% to $28.89 in pre-market trading. Trump Media & Technology Group shares dipped around 10% on Tuesday after the U.S. SEC declared effectiveness of the registration statement on Form S-1 rel
JP Morgan analyst Tycho Peterson maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54.
On Monday, Qiagen NV (NYSE:QGEN) announced at its Capital Markets Day a comprehensive strategy aimed at delivering solid and profitable growth through 2028. The company targets a 7% compound annual sales growth at constant exchange rates (CER) by 2028. At the event, the German molecular diagnostics firm announced its plans to return at least $1 billion to shareholders from 2024 to 2028, barring value-creating M&A opportunities while maintaining high levels of organic business investments. Key strategic pillars for growth include: QIAcuity Digital PCR: Plans include tripling the sales team to drive adoption, launching over 100 new assays, and seeking U.S. regulatory clearance for
Reuters reports.
QIAGEN's leadership team will present the new 2028 targets, highlighting vision and strategy to sharpen its focus on growth pillars in the portfolio combined with commitments to solid profitable growth and disciplined capital allocation. This includes plans to return at least $1 billion to shareholders from 2024-2028, absent value-creating M&A opportunities, along with a high level of organic business investments. QIAGEN has set a goal for at least $2 billion of combined annual sales in 2028 from its pillars amid plans for new product launches and important investments.
The company expects to deliver solid profitable growth through 2028 – led by about 7% compound annual sales growth (CAGR) at constant exchange rates (CER) during the four-year period and achieving at least a 31% CER adjusted operating income margin in 2028.
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer
JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight. “On behalf of the Supervisory Board and Managing Board, I would like to welcome Th
HSBC Securities downgraded Qiagen from Buy to Hold and set a new price target of $49.00
Wolfe Research upgraded Qiagen from Peer Perform to Outperform and set a new price target of $50.00
Wells Fargo initiated coverage of Qiagen with a rating of Equal Weight and set a new price target of $44.00
Wolfe Research initiated coverage of Qiagen with a rating of Peer Perform
Goldman upgraded Qiagen from Neutral to Buy and set a new price target of $50.00
Robert W. Baird initiated coverage of Qiagen with a rating of Outperform and set a new price target of $50.00
Morgan Stanley upgraded Qiagen from Equal-Weight to Overweight
Morgan Stanley initiated coverage of Qiagen with a rating of Equal-Weight
DZ Bank upgraded Qiagen from Hold to Buy
Wells Fargo reiterated coverage of Qiagen with a rating of Equal-Weight and set a new price target of $60.00 from $58.00 previously
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
6-K - QIAGEN N.V. (0001015820) (Filer)
SD - QIAGEN N.V. (0001015820) (Filer)
S-8 - QIAGEN N.V. (0001015820) (Filer)
20-F - QIAGEN N.V. (0001015820) (Filer)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)